Candel Therapeutics (CADL) and IDEA Pharma said Thursday they have entered a commercial partnership to support the development and potential market launch of Candel's lead candidate CAN-2409.
As part of the agreement, set to continue through next year, IDEA will provide strategic guidance as Candel prepares a biologics license application for CAN-2409 in prostate cancer, the companies said.
The partnership follows encouraging late-stage results showing the treatment improved disease-free survival and reduced recurrence, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.